Corcept Therapeutics (CORT) Invested Capital (2016 - 2025)
Corcept Therapeutics (CORT) has disclosed Invested Capital for 14 consecutive years, with $647.8 million as the latest value for Q4 2025.
- Quarterly Invested Capital fell 4.68% to $647.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $647.8 million through Dec 2025, down 4.68% year-over-year, with the annual reading at $647.8 million for FY2025, 4.68% down from the prior year.
- Invested Capital hit $647.8 million in Q4 2025 for Corcept Therapeutics, up from $631.9 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $683.3 million in Q1 2025 to a low of $375.8 million in Q4 2021.
- Historically, Invested Capital has averaged $537.8 million across 5 years, with a median of $526.1 million in 2021.
- Biggest five-year swings in Invested Capital: decreased 28.19% in 2021 and later soared 41.42% in 2024.
- Year by year, Invested Capital stood at $375.8 million in 2021, then skyrocketed by 33.54% to $501.8 million in 2022, then increased by 0.97% to $506.7 million in 2023, then skyrocketed by 34.12% to $679.6 million in 2024, then fell by 4.68% to $647.8 million in 2025.
- Business Quant data shows Invested Capital for CORT at $647.8 million in Q4 2025, $631.9 million in Q3 2025, and $635.8 million in Q2 2025.